BRNS (Barinthus Biotherapeutics) PEG Ratio: N/A (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BRNS Barinthus Biotherapeutics PLC BRNS
52 GF Score
Price $0.61
GF Value $1.12
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Barinthus Biotherapeutics's PE Ratio without NRI is 0.00. Barinthus Biotherapeutics's 5-Year EBITDA growth rate is 0.00%. Therefore, Barinthus Biotherapeutics's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Barinthus Biotherapeutics's PEG Ratio or its related term are showing as below:



BRNS's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.97
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Barinthus Biotherapeutics  (NAS:BRNS) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Barinthus Biotherapeutics PEG Ratio Related Terms


Barinthus Biotherapeutics PEG Ratio Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics PEG Ratio Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Barinthus Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BRNS vs VTGN, PSTV, PVCT: PEG Ratio Comparison

For the Biotechnology subindustry, Barinthus Biotherapeutics's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Barinthus Biotherapeutics PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's PEG Ratio falls into.


BRNS
52GF Score
Barinthus Biotherapeutics PLC BRNS
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Barinthus Biotherapeutics's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Barinthus Biotherapeutics (BRNS) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of $0.61 is trading 45.8% below its estimated GF Value™ of $1.12. GuruFocus considers Barinthus Biotherapeutics to be Possible Value Trap.

Key valuation signals for BRNS:

  • PEG Ratio: N/A
  • GF Value™: $1.12 vs. price of $0.61 (45.8% below fair value)
  • GF Score™: 52/100 with 1 warning sign

No single metric tells the full story. See the BRNS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Barinthus Biotherapeutics Business Description

Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
52GF Score

Get the complete analysis for BRNS

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.61
Price
$1.12
GF Value